<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236768</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL13</org_study_id>
    <nct_id>NCT01236768</nct_id>
  </id_info>
  <brief_title>Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm</brief_title>
  <acronym>ATI-CL13</acronym>
  <official_title>An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System in Comparison to an Oral Contraceptive (OC) Containing 150 mcg LNG and 30 mcg EE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal
      contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative evaluation of AG200-15 versus OC with regard to safety, contraceptive efficacy,
      hormone related adverse events, lipid profile, cycle control (bleeding pattern), subject
      compliance and serum concentrations of EE and LNG. To evaluate TCDS wearability (including
      adhesion).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Reported as Pearl Index</measure>
    <time_frame>6 months</time_frame>
    <description>Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cycle Control</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of cycles with breakthrough bleeding or spotting episodes during all cycles. Numerator is total number of cycles with event, denominator is total number of cycles.</description>
  </other_outcome>
  <other_outcome>
    <measure>Irritation and Itching at Application Site</measure>
    <time_frame>6 months</time_frame>
    <description>AG200-15 irritation and itching scores are defined as follows:
0=none
mild
moderate
severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics of Levonorgestrel (LNG) and Ethinyl Estradiol (EE)</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Measurement of plasma levels of levonorgestrel and ethinyl estradiol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adhesion at Application Site</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of adhesion of application site is defined as follows:
0: &gt;=90% adhered (no lifting)
&gt;=75% adhered but &lt;90% (some edges showing lifting)
&gt;=50% adhered but &lt;75% (half of the patch lifts off)
&lt;50% (&gt; half of patch lifts off, but not detached)
patch completely detached</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>AG200-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levora</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral contraceptive containing 150mcg of LNG and 30mcg of EE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG200-15</intervention_name>
    <description>Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
    <arm_group_label>AG200-15</arm_group_label>
    <other_name>Transdermal contraceptive delivery system (TCDS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levora</intervention_name>
    <description>One tablet of Levora will be taken each day for a 28 day cycle.</description>
    <arm_group_label>Levora</arm_group_label>
    <other_name>Hormonal oral contraceptive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sexually active women requesting contraception

          -  Regular menses every 24 - 35 days

          -  In good general health, confirmed by medical history, physical (including gynecologic
             examination adn screening laboratory values

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Lactating women

          -  Significant skin reaction to transdermal preparations or sensitivity to surgical /
             medical tape

          -  Any disease that may worsen under hormonal treatment (cardiovascular, liver,
             metabolic)

          -  Use of other contraceptive methods than study medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Foegh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Agile Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Valley</city>
        <state>Arizona</state>
        <zip>85614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kernersville</city>
        <state>North Carolina</state>
        <zip>27284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <disposition_first_submitted>July 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2013</disposition_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraceptive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Hormonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AG200-15</title>
          <description>Transdermal contraceptive delivery system (TCDS)</description>
        </group>
        <group group_id="P2">
          <title>Levora</title>
          <description>hormonal oral contraceptive</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population (number of subjects that received drug)</population>
      <group_list>
        <group group_id="B1">
          <title>AG200-15</title>
          <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
        </group>
        <group group_id="B2">
          <title>Levora</title>
          <description>hormonal oral contraceptive</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pregnancy Reported as Pearl Index</title>
        <description>Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
        <time_frame>6 months</time_frame>
        <population>Intent-to-treat population ages 18-35.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
          <group group_id="O2">
            <title>Levora</title>
            <description>hormonal oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Reported as Pearl Index</title>
          <description>Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
          <population>Intent-to-treat population ages 18-35.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" lower_limit="0.19" upper_limit="16.19"/>
                    <measurement group_id="O2" value="6.80" lower_limit="0.15" upper_limit="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Adverse events</description>
        <time_frame>6 months</time_frame>
        <population>Any subject who applied a patch.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
          <group group_id="O2">
            <title>Levora</title>
            <description>oral contraceptive containing 150mcg of LNG and 30mcg of EE
Levora: One tablet of Levora will be taken each day for a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Adverse events</description>
          <population>Any subject who applied a patch.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cycle Control</title>
        <description>The percentage of cycles with breakthrough bleeding or spotting episodes during all cycles. Numerator is total number of cycles with event, denominator is total number of cycles.</description>
        <time_frame>6 months</time_frame>
        <population>Subjects with relevant breakthrough bleeding (BTB) and/or spotting (BTS), and drug information for a cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
          <group group_id="O2">
            <title>Levora</title>
            <description>oral contraceptive containing 150mcg of LNG and 30mcg of EE
Levora: One tablet of Levora will be taken each day for a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Cycle Control</title>
          <description>The percentage of cycles with breakthrough bleeding or spotting episodes during all cycles. Numerator is total number of cycles with event, denominator is total number of cycles.</description>
          <population>Subjects with relevant breakthrough bleeding (BTB) and/or spotting (BTS), and drug information for a cycle.</population>
          <units>percent cycles with BTB or BTS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparative evaluation of AG200-15 and Levora</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparative analysis of AG200-15 and Levora for breakthrough bleeding and/or spotting.</non_inferiority_desc>
            <p_value>0.089</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Irritation and Itching at Application Site</title>
        <description>AG200-15 irritation and itching scores are defined as follows:
0=none
mild
moderate
severe</description>
        <time_frame>6 months</time_frame>
        <population>Subject self-reported worse irritation score in a cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
        </group_list>
        <measure>
          <title>Irritation and Itching at Application Site</title>
          <description>AG200-15 irritation and itching scores are defined as follows:
0=none
mild
moderate
severe</description>
          <population>Subject self-reported worse irritation score in a cycle.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Irritation Score (cycles 1-6 combined)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Score (cycles 1-6 combined)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetics of Levonorgestrel (LNG) and Ethinyl Estradiol (EE)</title>
        <description>Measurement of plasma levels of levonorgestrel and ethinyl estradiol.</description>
        <time_frame>3 months and 6 months</time_frame>
        <population>Number of subjects with available LNG data for cycle 3 or cycle 6</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
          <group group_id="O2">
            <title>Levora</title>
            <description>oral contraceptive containing 150mcg of LNG and 30mcg of EE
Levora: One tablet of Levora will be taken each day for a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Levonorgestrel (LNG) and Ethinyl Estradiol (EE)</title>
          <description>Measurement of plasma levels of levonorgestrel and ethinyl estradiol.</description>
          <population>Number of subjects with available LNG data for cycle 3 or cycle 6</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LNG cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2244" lower_limit="1887" upper_limit="2600"/>
                    <measurement group_id="O2" value="3474" lower_limit="3044" upper_limit="3904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LNG cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1743" lower_limit="1478" upper_limit="2007"/>
                    <measurement group_id="O2" value="3682" lower_limit="3136" upper_limit="4228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EE cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" lower_limit="38.7" upper_limit="50.3"/>
                    <measurement group_id="O2" value="50.6" lower_limit="43.0" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EE cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="30.1" upper_limit="39.4"/>
                    <measurement group_id="O2" value="54.7" lower_limit="44.8" upper_limit="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adhesion at Application Site</title>
        <description>Measurement of adhesion of application site is defined as follows:
0: &gt;=90% adhered (no lifting)
&gt;=75% adhered but &lt;90% (some edges showing lifting)
&gt;=50% adhered but &lt;75% (half of the patch lifts off)
&lt;50% (&gt; half of patch lifts off, but not detached)
patch completely detached</description>
        <time_frame>6 months</time_frame>
        <population>Subjects that have documented adhesion scores.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
          </group>
        </group_list>
        <measure>
          <title>Adhesion at Application Site</title>
          <description>Measurement of adhesion of application site is defined as follows:
0: &gt;=90% adhered (no lifting)
&gt;=75% adhered but &lt;90% (some edges showing lifting)
&gt;=50% adhered but &lt;75% (half of the patch lifts off)
&lt;50% (&gt; half of patch lifts off, but not detached)
patch completely detached</description>
          <population>Subjects that have documented adhesion scores.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AG200-15</title>
          <description>Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
AG200-15: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week &quot;patch free&quot; period.</description>
        </group>
        <group group_id="E2">
          <title>Levora</title>
          <description>oral contraceptive containing 150mcg of LNG and 30mcg of EE
Levora: One tablet of Levora will be taken each day for a 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Murine Typhus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Review and approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL13 study is required prior to publication submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Flood, Associate Director of Clinical Operations</name_or_title>
      <organization>Agile Therapeutics</organization>
      <phone>609-683-1880</phone>
      <email>lflood@agiletherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

